Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 6/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586449 | 0.91 | USP30 (0.42) | RORCCDK1CCNB2CCNB1GSK3B | |
| SCHEMBL17586448 | 0.89 | ALK (0.43) | RORCCDK1CCNB2CCNB1GSK3B | |
| SCHEMBL30476256 | 0.84 | PDK2 (0.37) | RORCUSP30PDK2ALKESR2 | |
| SCHEMBL30476276 | 0.84 | HSD11B1 (0.46) | PDK2PDK4 | |
| SCHEMBL30508369 | 0.80 | AVPR1A (0.48) | CDK1CCNB2CCNB1GSK3BCCNB3 | |
| SCHEMBL20502778 | 0.79 | RORC (0.41) | RORCBACE1ROCK2USP30ESR2 | |
| SCHEMBL30476239 | 0.78 | USP30 (0.41) | RORCROCK2USP30PDK2ESR2 | |
| SCHEMBL17586456 | 0.77 | OPRM1 (0.40) | BACE1 | |
| SCHEMBL12097232 | 0.75 | RORC (0.40) | RORCBACE1ROCK2USP30ESR2 | |
| SCHEMBL349129 | 0.75 | HSD11B1 (0.55) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47636-E1 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| EP-3191487-B1 | SPIROCYCLIC INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3511331-A1 | SPIROCYCLIC INHIBITORS OF CATHEPSIN C | Boehringer Ingelheim International GmbH (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-9879026-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9879026-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-20170073352-A1 | NOVEL SUBSTITUTED SPIROCYCLES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073352-A1 | NOVEL SUBSTITUTED SPIROCYCLES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-16 | — | — | US | disclosed |
| US-9540373-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540373-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20160075704-A1 | NOVEL SUBSTITUTED SPIROCYCLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075704-A1 | NOVEL SUBSTITUTED SPIROCYCLES | CTSC, CTSE, CTSS | RORC 218/4885CDK1 2371/4885CCNB2 3379/4885 |
| US-20170073352-A1 | NOVEL SUBSTITUTED SPIROCYCLES | CTSC, CTSE, CTSS | RORC 218/4885CDK1 2371/4885CCNB2 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.